SequelSEC

Alector, Inc. ALEC

Biological Products, (No Diagnostic Substances) · CIK 0001653087 · Fiscal year ends 1231

Revenue
$13.86M
Fiscal year ended 2026-06-30
Operating income
-$126.49M
Fiscal year ended 2026-06-30
Free cash flow
-$158.39M
Fiscal year ended 2026-06-30

Alector, Inc. (ALEC) reported revenue of $13.86M and net income of -$117.85M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Alector, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Alector, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$13.86M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$126.49M
Net income-$117.85M
Research & development$99.13M
Weighted-average diluted sharesUnavailable
Pretax income-$117.56M
Income tax expense$298.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$41.22M
Selling & marketingUnavailable

Balance

Alector, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$59.92M
Total assets$202.86M
Current assets$180.09M
Total liabilities$212.82M
Current liabilities$34.24M
Total equity incl. NCI-$9.97M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debt$0
Accounts payable$2.28M

Cash flow

Alector, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$158.23M
Capital expenditures$160.00K
Investing cash flow$153.21M
Financing cash flow$20.17M
Net change in cash$15.14M
Stock-based compensation$16.76M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$4.54M

Derived

Alector, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$158.39M
Gross marginUnavailable
Operating margin-912.4%
FCF margin-1142.6%
SBC / revenue120.9%
Current ratio5.26x
Revenue YoY growth-82.9%
Net margin-850.1%
R&D / revenue715.1%
CapEx / revenue1.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALEC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.